Drugs / OMP-336B11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03295942 | Sep 2017 → Jul 2019 | metastatic malignant neoplasm | OncoMed Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMP-336B11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03295942 ↗ |
| Action | Activate | “activate the immune system to recognize and eliminate cancer cells” NCT03295942 ↗ |
| Modality | Protein / enzyme biologic | “engineered human protein” NCT03295942 ↗ |
| Route | Intravenous | “Intravenous (in the vein) infusions of OMP-336B11” NCT03295942 ↗ |